<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946347</url>
  </required_header>
  <id_info>
    <org_study_id>G981</org_study_id>
    <nct_id>NCT01946347</nct_id>
  </id_info>
  <brief_title>Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects</brief_title>
  <acronym>EndoPat</acronym>
  <official_title>Effect of Hyperinsulinemia and Postprandial Metabolic Changes on Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of hyperinsulinemia and postprandial changes&#xD;
      in plasma glucose and lipids concentrations on the endothelial function together with other&#xD;
      metabolic parameters in patients with type 2 diabetes (T2D) and in healthy subjects.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Different changes in endothelial function to acute in vivo induced hyperinsulinemia and after&#xD;
      the meal test will be found in patients with T2D compared to healthy subjects.&#xD;
&#xD;
      A significant relationships between insulin sensitivity, selected adipokines intramyocellular&#xD;
      fat content, hepatic fat content and high energy phosphates in soleus muscle will be&#xD;
      documented in both groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 patients with T2D and 30 healthy control subjects will be examined on an outpatient basis.&#xD;
      The following examination will be carried out in each subject after 12 hrs fasting:&#xD;
&#xD;
        -  Hyperinsulinaemic euglycemic clamp study lasting 4 hours combined with indirect&#xD;
           calorimetry and biopsy of subcutaneous adipose tissue and muscle aspiration biopsy&#xD;
&#xD;
        -  Meal test:Plasma glucose, immunoreactive insulin, plasma lipids, oxidative stress&#xD;
           markers and gastrointestinal peptides measured in response to a standard meal(at times&#xD;
           0´,30´,60´,120´,180´)&#xD;
&#xD;
        -  At the beginning and after 120 minutes during the meal test and clamp peripheral&#xD;
           microvascular endothelial function will be measured using EndoPat(Itamar Medical)&#xD;
&#xD;
        -  Proton and phosphorus magnetic resonance spectroscopy(MRS).&#xD;
&#xD;
        -  Dual Energy X-ray Absorptiometry(DXA) scanning to measure body composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of endothelial function (measured by EndoPat)</measure>
    <time_frame>120 minutes</time_frame>
    <description>at 0 and after 120 minutes during the clamp and 120 minutes after meal ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrointestinal peptides concentrations</measure>
    <time_frame>180 minutes</time_frame>
    <description>0, 30, 60, 120, 180 minutes after meal ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxidative stress markers</measure>
    <time_frame>120 minutes</time_frame>
    <description>at 0 and after 120 minutes after meal ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity measured as glucose disposal during clamp</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mixed meal</intervention_name>
    <description>Baguette Cheese Gourmet (Crocodile:&#xD;
180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acute in vivo induced hyperinsulinemia</intervention_name>
    <description>Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with T2D:&#xD;
&#xD;
        Inclusion criteria -&#xD;
&#xD;
          1. Men and women aged 30-65 years&#xD;
&#xD;
          2. Body Mass Index in the range of 25 - 45(kg/m2)&#xD;
&#xD;
          3. Type 2 diabetes mellitus for at least one year&#xD;
&#xD;
          4. Treatment of T2D: diet or oral antidiabetic agents (stable drug therapy at least 3&#xD;
             months before the trial&#xD;
&#xD;
          5. The presence of metabolic syndrome - any three of the following symptoms:&#xD;
&#xD;
               1. Abdominal obesity - waist circumference in men &gt;102 cm, in women &gt;88 cm&#xD;
&#xD;
               2. Diagnosis and treatment of type 2 diabetes&#xD;
&#xD;
               3. Raised blood pressure (BP): systolic BP &gt; 130 mm Hg or diastolic BP &gt;85 mm Hg, or&#xD;
                  treatment of previously diagnosed hypertension&#xD;
&#xD;
               4. Reduced HDL cholesterol in men &lt; 1 mmol/l, in women &lt; 1,3 mmol/l (or treatment)&#xD;
&#xD;
               5. Raised triglycerides &gt; 1,7 mmol/l (or treatment)&#xD;
&#xD;
        4. HbA1c ≥ 42 a ≤100 mmol/mol&#xD;
&#xD;
        Exclusion criteria -&#xD;
&#xD;
          1. Type 1 diabetes mellitus&#xD;
&#xD;
          2. Unstable drug therapy at least 3 month before the trial&#xD;
&#xD;
          3. Pregnancy, breast feeding or trying to become pregnant&#xD;
&#xD;
          4. Alcoholism or drug use&#xD;
&#xD;
          5. Presence of other medical condition, which occurs during physical examination,&#xD;
             laboratory tests, including pulmonary, neurological or inflammatory disease, which&#xD;
             would be considered by the examiner to distort the consistency of data&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
        Inclusion criteria -&#xD;
&#xD;
          1. Men and women aged 30-65 years&#xD;
&#xD;
          2. Body Mass Index 25-45 (kg/m2)&#xD;
&#xD;
          3. Absence of metabolic syndrome - not more than any two of the following symptoms:&#xD;
&#xD;
               1. Abdominal obesity - waist circumference in men &gt;102 cm, in women &gt;88 cm&#xD;
&#xD;
               2. Diagnosis and treatment of type 2 diabetes or raised fasting plasma glucose level&#xD;
                  (FPG &gt;5,6 mmol/l)&#xD;
&#xD;
               3. Raised blood pressure (BP): systolic BP &gt;130 mm Hg or diastolic BP &gt;85 mm Hg, or&#xD;
                  treatment of previously diagnosed hypertension&#xD;
&#xD;
               4. Reduced HDL cholesterol in men &lt;1 mmol/l, in women &lt;1,3 mmol/l(or treatment)&#xD;
&#xD;
               5. Raised triglycerides &gt; 1,7 mmol/l (or treatment)&#xD;
&#xD;
        Exclusion criteria -&#xD;
&#xD;
          1. Diabetes or impaired glucose tolerance (HbA1c ≥40 mmol/mol and/or FPG &gt;5,6 mmol/l),&#xD;
             diagnosed diabetes in first-line relatives&#xD;
&#xD;
          2. Pregnancy, breast feeding or trying to become pregnant&#xD;
&#xD;
          3. Alcoholism or drug use&#xD;
&#xD;
          4. Presence of other medical condition, which occurs during physical examination,&#xD;
             laboratory tests, including pulmonary, neurological or inflammatory disease, which&#xD;
             would be considered by the examiner to distort the consistency of data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terezie Pelikanova, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Terezie Pelikanova</investigator_full_name>
    <investigator_title>Prof.MUDr.Terezie Pelikanova DrSc.</investigator_title>
  </responsible_party>
  <keyword>Insulin Resistance</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

